Pharmaceutical considerations for fracture management in adults Fractures can cause significant morbidity and mortality and require a multidisciplinary approach for the best patient outcomes.…
Rheumatoid arthritis: management An overview of the medicines used for symptom control and disease modification, with consideration given to non-pharmacological approaches that support management of rheumatoid arthritis.…
Risk assessment for rheumatoid arthritis drug could result in fewer blood tests for patients, research suggests Researchers have developed a risk-stratified monitoring system for toxicity linked to methotrexate to determine a patient's risk of abnormal blood test results.…
NSAIDs fail to reduce joint inflammation for people with arthritis of the knee, study results show Comparing two groups of people with synovitis, researchers found that those treated with long-term oral non-steroidal anti-inflammatory drugs had worse synovitis than those not treated with the drugs.…
Pharmacy guide to joint pain: case studies Example case studies and consultations to help guide pharmacy teams on how to best manage patients presenting with joint pain symptoms in community pharmacy.… Supported content
Pharmacy guide to joint pain: management A guide, including an algorithm, for pharmacy teams on how to effectively manage patients presenting with joint pain symptoms in community pharmacy.… Supported content
Pharmacy guide to joint pain: diagnosis and assessment A guide for pharmacy teams on how to effectively assess patients presenting with joint pain symptoms in community pharmacy.… Supported content
Appropriate community pharmacy management of joint pain A summary of best practice joint pain management recommendations for use by community pharmacy teams.… Supported content
‘Milestone’ as NICE recommends biologics in moderate rheumatoid arthritis for the first time Updated guidance from the National Institute for Health and Care Excellence will increase access to advanced therapies adalimumab, etanercept and infliximab within the NHS.…
Draft NICE guidance recommends first biologics for treatment of moderate rheumatoid arthritis Final draft guidance from the National Institute for Health and Care Excellence states that adalimumab, etanercept and infliximab are recommended in the treatment of moderate rheumatoid arthritis.…
